The present results show that levels of serum AT1-AA (AT1 receptor agonists) and ACE2-AA (ACE2 antagonists) are significantly higher in PD patients than in non-PD controls, possibly as a consequence of the dopaminergic degeneration and the corresponding neuroinflammatory changes. This evidence concerns the gene AGTR1 and Parkinson disease.